

PERSONAL INFORMATION

Rossella Manfredini



📍 Strada Borelle 99/2, 41126 Modena (MO) Italy

☎ +39 059 2058065

✉ rossella.manfredini@unimore.it

🌐 <https://www.cmr.unimore.it/en/equipe/rossella-manfredini/>

Sex Female | Date of birth 2/11/1962 | Nationality Italian

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input checked="" type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist
<input type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

WORK EXPERIENCE

November 2024-present	Coordinator, PhD Program in Molecular and Regenerative Medicine, University of Modena and Reggio Emilia
November 2024-present	Director, Interdepartmental Center for Genome Research, University of Modena and Reggio Emilia
March 2013-present	Full professor in Applied Biology
2002-Feb 2013	Associate Professor in Applied Biology University of Modena and Reggio Emilia Via Campi 287 41125 Modena (MO) Italy
2010-present	Genomics e Transcriptomics Program Coordinator, Centre for Regenerative Medicine "S. Ferrari", University of Modena and Reggio Emilia, Via Gottardi 100 41125 Modena, (MO) Italy
2008-2010	Director of Flow Cytometry Laboratory, Department of Biomedical Sciences University of Modena and Reggio Emilia Via G. Campi 287 41125 Modena (MO) Italy
1996-2002	Researcher in Applied Biology Department of Biomedical Sciences University of Modena and Reggio Emilia Via G. Campi 287 41125 Modena (MO) Italy

EDUCATION AND TRAINING

1996	Postgraduate (summa con laude) in Biochemistry and Clinical Chemistry School of Biochemistry and Clinical Chemistry University of Modena, School of Medicine, Italy
1994	PhD in Experimental Hematology School of Clinical and Experimental Hematology, University of Modena, School of Medicine, Italy
6/11/1986	Biological Sciences Degree (summa con laude), University of Modena, Italy

WORK ACTIVITIES

Editorial activities	She usually serves as a reviewer for high-impact journal, such as Blood, Leukemia, Nature Communications, Haematologica, Cell Death and Differentiation, Blood Cancer Journal.
----------------------	--

- Research Topics:
1. Gene expression regulation in normal and leukemic differentiation.
 2. Gene expression profiling of hematopoietic stem cells, myeloid precursors and differentiated cells.
 3. Gene expression profiling of Leukemic Stem Cells (LSC) of myeloproliferative neoplasms
 4. Regulatory mRNA/microRNA networks in Leukemic Stem Cells (LSC) of myeloproliferative neoplasms.
 5. Study of the in vivo homing and engraftment capacity of normal and leukemic hematopoietic stem cell subpopulations.
 6. Study of the hierarchy and clonal heterogeneity of the stem compartment in chronic myeloproliferative neoplasms by single-cell analysis.
 7. Identification of Leukemic Stem Cell Subpopulations in Chronic Myeloproliferative Neoplasms.

- Grants
(last 10 years)
1. 2010-2017 AIRC-Italian Association for Cancer Research-5 X 1000-SPECIAL PROGRAM IN MOLECULAR ONCOLOGY; Research Program Topic ": "An integrated platform for molecular studies and clinical trials in chronic myeloproliferative neoplasm".
 2. 2012-2014- FIRB-Accordo ex art.7 del D.M. 378 del 26/03/04; Research Program Topic "An Integrated Biomolecular Approach To Discover Novel Therapeutic Targets In Chronic Myeloproliferative Neoplasms".
 3. 2012-2014- Italian Association for Cancer Research--INVESTIGATOR GRANT; Research AIRC-Program Topic ": "Molecular mechanisms underlying Myb-driven megacaryocytopoiesis and role in Myeloproliferative Neoplasms".
 4. 2012-2015: PRIN PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE: Research program topic: "Coding and non-coding RNA in myeloproliferative neoplasms and myelodysplastic syndromes: pathogenetic and therapeutic implications".
 5. 2015-2017 Italian Association for Cancer Research--INVESTIGATOR GRANT; Research AIRC-Program Topic: "The role of mutated Calreticulin in myeloproliferative neoplasms: understanding molecular pathogenesis"
 6. 2018-2022 Italian Association for Cancer Research--INVESTIGATOR GRANT; Research AIRC-Program Topic: Clonal hierarchy and clonal evolution of myeloproliferative neoplasms in chronic phase and during disease progression.
 7. 2019-2021 Italian Ministry of Health Progetti ordinari di Ricerca Finalizzata: Program Topic: Exploiting calreticulin mutations as a model for personalized medicine in myeloproliferative neoplasms.
 8. 2018-2025: Italian Association for Cancer Research-5 X 1000-SPECIAL PROGRAM IN MOLECULAR ONCOLOGY; Research AIRC- Program Topic: "Actionable targets in clonal progression and systemic spreading of myeloid neoplasms".
 9. 2019-2021: Italian Ministry of Research MIUR: PRIN PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE: Research program topic: " Myeloid Neoplasms: an integrated clinical, molecular and therapeutic approach "
 10. 2023-2025: Italian Ministry of Research MIUR: PRIN PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE: Research program topic: "Understanding response or resistance to JAK inhibitors in myeloproliferative neoplasms through Single-cell genomics and transcriptomics".
 11. 2023-2025: Italian Ministry of University and Research under PNRR—M4C2-I1.3 Project PE_00000019 "HEAL ITALIA".
 12. 2024-2028: Italian Association for Cancer Research--INVESTIGATOR GRANT; Research AIRC-Program Topic: "Characterizing Myelofibrosis stem cells for the identification of novel druggable targets.
 13. 2026-2029: Italian Ministry of Health Progetti ordinari di Ricerca Finalizzata: Program Topic Dissecting genetic complexity of myeloproliferative neoplasms-blast phase for patients risk stratification and novel therapeutic targets discovery: insights from multi-omic interrogation of the prospective ENABLE trial".

ADDITIONAL INFORMATION

Publications (Selection of last 10 years)

1. Tavernari L, Bertesi M, Neroni A, Papa E, Rontautoli S, Bianchi E, Mirabile M, Norfo R, Parenti S, Tombari C, Carretta C, Malerba M, Fabbiani L, Guglielmelli P, Losi L, Tagliafico E, Vannucchi AM, **Manfredini R**; MYNERVA (MYeloid NEoplasms Research Venture AIRC) investigators. Combined MEK and JAKinhibition reduces

osteopontin plasma level and bone marrow fibrosis in a myelofibrosis mouse model. *Blood Cancer J.* 2025 Nov 15;15(1):197. doi:10.1038/s41408-025-01409-3. PMID: 41238572; PMCID: PMC12618570.

2. Mirabile M, Tombari C, Neroni A, Tavernari L, Norfo R, Bianchi E, Maccaferri M, Mora B, Parenti S, Carretta C, Bertesi M, Malerba M, Papa E, Fabbiani L, Bartalucci N, Guglielmelli P, Potenza L, Losi L, Passamonti F, Tagliafico E, Luppi M, Rontauoli S, Vannucchi AM, **Manfredini R**; MYNERVA (Myeloid NEoplasms Research Venture AIRC) investigators. CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis. *J Cell Mol Med.* 2025 Jul;29(14):e70720. doi: 10.1111/jcmm.70720. PMID: 40690545; PMCID: PMC12279041.
3. Tavernari L, Rontauoli S, Norfo R, Mirabile M, Maccaferri M, Mora B, Genovese E, Parenti S, Carretta C, Bianchi E, Bertesi M, Pedrazzi F, Tenedini E, Martinelli S, Bochicchio MT, Guglielmelli P, Potenza L, Lucchesi A, Passamonti F, Tagliafico E, Luppi M, Vannucchi AM, **Manfredini R**; MYNERVA (Myeloid NEoplasms Research Venture AIRC) investigators. Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts. *Am J Hematol.* 2024 Oct;99(10):1939-1950. doi: 10.1002/ajh.27428. Epub 2024 Jul 2. PMID: 38953347.
4. Carretta C, Parenti S, Bertesi M, Rontauoli S, Badii F, Tavernari L, Genovese E, Malerba M, Papa E, Sperduti S, Enzo E, Mirabile M, Pedrazzi F, Neroni A, Tombari C, Mora B, Maffioli M, Mondini M, Brociner M, Maccaferri M, Tenedini E, Martinelli S, Bartalucci N, Bianchi E, Casarini L, Potenza L, Luppi M, Tagliafico E, Guglielmelli P, Simoni M, Passamonti F, Norfo R, Vannucchi AM, **Manfredini R**; MYNERVA (Myeloid NEoplasms Research Venture AIRC). Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms. *Leukemia.* 2024 Oct;38(10):2171-2182. doi: 10.1038/s41375-024-02373-w. Epub 2024 Aug 23. PMID: 39179669; PMCID: PMC11436358.
5. Calabresi L, Carretta C, Romagnoli S, Rotunno G, Parenti S, Bertesi M, Bartalucci N, Rontauoli S, Chiereghin C, Castellano S, Gentili G, Maccari C, Vanderwert F, Mannelli F, Della Porta M, **Manfredini R***, Vannucchi AM*, Guglielmelli P*. Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms. *Am J Hematol.* 2023 Jul 3. doi: 10.1002/ajh.27013. Epub ahead of print. PMID: 37399248. * senior authors
6. Bianchi E, Rontauoli S, Tavernari L, Mirabile M, Pedrazzi F, Genovese E, Sartini S, Dall'Ora M, Grisendi G, Fabbiani L, Maccaferri M, Carretta C, Parenti S, Fantini S, Bartalucci N, Calabresi L, Balliu M, Guglielmelli P, Potenza L, Tagliafico E, Losi L, Dominici M, Luppi M, Vannucchi AM, **Manfredini R**. Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. *Leukemia* (2023). <https://doi.org/10.1038/s41375-023-01867-3>.
7. Rontauoli S, Carretta C, Parenti S, Bertesi M, **Manfredini R**. On Behalf Of The Mynerva MYeloid NEoplasms Research Venture Airc. Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective. *Int J Mol Sci.* 2022 Dec 3;23(23):15256. doi: 10.3390/ijms232315256. PMID: 36499582
8. Genovese E, Mirabile M, Rontauoli S, Sartini S, Fantini S, Tavernari L, Maccaferri M, Guglielmelli P, Bianchi E, Parenti S, Carretta C, Mallia S, Castellano S, Colasante C, Balliu M, Bartalucci N, Palmieri R, Ottone T, Mora B, Potenza L, Passamonti F, Voso MT, Luppi M, Vannucchi AM, Tagliafico E, **Manfredini R**, On Behalf Of The Mynerva MYeloid NEoplasms Research Venture Airc. The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. *Antioxidants (Basel)* . 2022 Jan 5;11(1):113. doi: 10.3390/antiox11010113. PMID: 35052617.
9. S Fantini, S, Rontauoli, S Sartini, M Mirabile, E Bianchi, F Badii, M Maccaferri, P Guglielmelli, T Ottone, R Palmieri, E Genovese, C Carretta, S Parenti, S Mallia, L Tavernari, C Salvadori, F Gesullo, C Maccari, M Zizza, A Grande, S Salmoiraghi, B Mora, L Potenza, V Rosti, F Passamonti, A Rambaldi, M T Voso, C Mecucci, E Tagliafico, M Luppi, A M Vannucchi, **R Manfredini**. Increased plasma levels of lncRNAs LINC01268, GAS5 and MALAT-1 correlate with negative prognostic factors in myelofibrosis. *Cancers (Basel)*. 2021 Sep 22;13(19):4744.
10. Riva G, Nasillo V, Ottomano AM, Bergonzini G, Paolini A, Forghieri F, Lusenti B, Barozzi P, Lagreca I, Fiorcari S, Martinelli S, Maffei R, Marasca R, Potenza L, Comoli P, **Manfredini R**, Tagliafico E, Trenti T, Luppi M. Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. *Cancers (Basel)*. 2021 Sep 12;13(18):4582. doi: 10.3390/cancers13184582.
11. Riva G, Castellano S, Nasillo V, Ottomano AM, Bergonzini G, Paolini A, Lusenti B, Milić J, De Biasi S, Gibellini L, Cossarizza A, Busani S, Girardis M, Guaraldi G, Mussini C, **Manfredini R**, Luppi M, Tagliafico E, Trenti T. Monocyte Distribution Width (MDW) as novel inflammatory marker with prognostic significance in COVID-19 patients. *Sci Rep* 2021 Jun 16;11(1):12716. doi: 10.1038/s41598-021-92236-.
12. Nasillo V, Riva G, Paolini A, Forghieri F, Roncati L, Lusenti B, Maccaferri M, Messerotti A, Pioli V, Gilioli A, Bettelli F, Giusti D, Barozzi P, Lagreca I, Maffei R, Marasca R, Potenza L, Comoli P, **Manfredini R**, Maiorana A, Tagliafico E, Luppi M, Trenti T. Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. *Int J Mol Sci.* 2021 Feb 14;22(4):1906.
13. S. Rontauoli, S. Castellano, P. Guglielmelli, R. Zini, E. Bianchi, E. Genovese, C. Carretta, S. Parenti, S. Fantini, S. Mallia, L. Tavernari, S. Sartini, M. Mirabile, C. Mannarelli, F. Gesullo, A. Pacilli, D. Pietra, E. Rumi, S. Salmoiraghi, B. Mora, L. Villani, A. Grilli, V. Rosti, G. Barosi, F. Passamonti, A. Rambaldi, L. Malcovati, M. Cazzola, S. Biciatto, E. Tagliafico, A.M. Vannucchi and **R. Manfredini**, on behalf of Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators. Gene expression profile correlates with molecular and clinical features in myelofibrosis patients. *Blood Advances, Blood Adv.* 2021 Mar 9;5(5):1452-1462.

14. Parenti S, Rontauoli S, Carretta C, Mallia S, Genovese E, Chiereghin C, Peano C, Bianchi E, Fantini S, Sartini S, Tavernari L, Romano O, Bicciato S, Tagliafico E, Della Porta M and **Manfredini R**. Mutated clones driving leukemic transformation are already detectable at the single cell level in CD34-positive cells in the chronic phase of primary myelofibrosis. *NPJ Precis Oncol*. 2021 Feb 4;5(1):4.
15. Balliu M, Calabresi L, Bartalucci N, Romagnoli S, Maggi L, Manfredini R, Lulli M, Guglielmelli P, Vannucchi AM. Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs. *Blood Adv*. 2021 Apr 27;5(8):2184-2195. doi: 10.1182/bloodadvances.2020003291.PMID: 33890979; PMCID: PMC8095134
16. Sceberas V, Attico E, Bianchi E, Galaverni G, Melonari M, Corradini F, Fantacci M, Ribbene A, Losi L, Balò S, Lazzeri M, Trombetta C, Rizzo M, Manfredini R, Barbagli G, Pellegrini G. Preclinical study for treatment of hypospadias by advanced therapy medicinal products. *World J Urol*. 2020 Sep;38(9):2115-2122. doi: 10.1007/s00345-019-02864-x. Epub 2019 Jul 9. PMID: 31289843.
17. Carretta C, Mallia S, Genovese E, Parenti S, Rontauoli S, Bianchi E, Fantini S, Sartini S, Tavernari L, Tagliafico E, **Manfredini R**, "Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol", *Int J Mol Sci*. 2020 Oct 6; 21 (19): E7366. doi: 10.3390 / ijms21197366.
18. Scherm MG, Serr I, Zahm AM, Schug J, Bellusci S, **Manfredini R**, Salb VK, Gerlach K, Weigmann B, Ziegler AG, Kaestner KH, Daniel C. miRNA142- 3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes. *Nat Commun*. 2019 Dec 13;10(1):5697.
19. Rotunno G, Mannarelli C, Brogi G, Pacilli A, Gesullo F, Mannelli F, Fiaccabrino S, Sordi B, Paoli C, Marone I, Rumi E, **Manfredini R**, Barosi G, Cazzola M, Vannucchi AM, Guglielmelli P. Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. *Blood* 2019 Jun 27;133(26):2802-2808.
20. Salati S, Genovese E, Carretta C, Zini R, Bartalucci N, Prudente Z, Pennucci V, Ruberti S, Rossi C, Rontauoli S, Enzo E, Calabresi L, Balliu M, Mannarelli C, Bianchi E, Guglielmelli P, Tagliafico E, Vannucchi AM, **Manfredini R**. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. *Sci Rep*. 2019 Jul 22;9(1):10558. doi: 10.1038/s41598-019-46843-z.
21. Rossi C, Zini R, Rontauoli S, Ruberti S, Prudente Z, Barbieri G, Bianchi E, Salati S, Genovese E, Bartalucci N, Guglielmelli P, Tagliafico E, Rosti V, Barosi G, Vannucchi AM, **Manfredini R**; AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative) investigators. Role of TGF- β 1/miR-382- 5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis. *Mol Oncol*. 2018 Dec;12(12):2102-2123. doi: 10.1002/1878-0261.12387. Epub 2018 Nov 16.
22. Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, Kingston N, Cheng Y, Lombardo K, Schorl C, Yu X, Zini R, Pacilli A, Tepper A, Coburn J, Hryniewicz-Jankowska A, Zhao TC, Oancea E, Reagan JL, Liang O, Kotula L, Quesenberry PJ, Gruppuso PA, **Manfredini R**, Vannucchi AM, Dubielecka PM. Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. *Blood*. 2018 Nov 8;132(19):2053-2066. doi: 10.1182/blood-2018-05-848408. Epub 2018 Sep 13.
23. Salati S, Prudente Z, Genovese E, Pennucci V, Rontauoli S, Bartalucci N, Mannarelli C, Ruberti S, Zini R, Rossi C, Bianchi E, Guglielmelli P, Tagliafico E, Vannucchi AM, **Manfredini R**. Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation. *Stem Cells Dev*. 2017 Dec 19. doi: 10.1089/scd.2017.0137.
24. Zini R, Guglielmelli P, Pietra D, Rumi E, Rossi C, Rontauoli S, Genovese E, Fanelli T, Calabresi L, Bianchi E, Salati S, Cazzola M, Tagliafico E, Vannucchi AM, **Manfredini R**; AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators. CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. *Blood Cancer J*, 2017, Dec 8;7(12):638.
25. Ruberti S, Bianchi E, Guglielmelli P, Rontauoli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, **Manfredini R**. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. *Leukemia* 2018 Feb;32(2):438-449
26. Zini R, Rossi C, Norfo R, Pennucci V, Barbieri G, Ruberti S, Rontauoli S, Salati S, Bianchi E, **Manfredini R**. miR-382-5p Controls Hematopoietic Stem Cell Differentiation Through the Downregulation of MXD1. *STEM CELLS DEV* 2016 Oct; 25: 1433-43.
27. Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, **Manfredini R**, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P. Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group. *AM J HEMATOL* 2016 Jul; 91: 681-6
28. S Salati, R Zini, S Nuzzo, P Guglielmelli, V Pennucci, Z Prudente, S Ruberti, S Rontauoli, R Norfo, E Bianchi, C Bogani, G Rotunno, T Fanelli, C Mannarelli, V Rosti, S Salmoiraghi, D Pietra, Se. Ferrari, G Barosi, A. Rambaldi, M. Cazzola, S Bicciato, E Tagliafico, A M. Vannucchi, and **R. Manfredini**, on behalf of the AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators. Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis. *Int J Cancer*. 2016 Apr 1;138(7):1657-

69.

29. Bianchi E, Bulgarelli J, Ruberti S, Rontauoli S, Sacchi G, Norfo R, Pennucci V, Zini R, Salati S, Prudente Z, Ferrari S, and **Manfredini R**. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated down-regulation of MAF. *Cell death diff*, 2015 Dec;22(12):1906-21
30. Pennucci V, Zini R, Norfo R, Guglielmelli P, Bianchi E, Salati S, Sacchi G, Prudente Z, Tenedini E, Ruberti S, Paoli C, Fanelli T, Mannarelli C, Tagliafico E, Ferrari S, Vannucchi AM, **Manfredini R**. Abnormal Expression of WT1-as, MEG3 and ANRIL Long Non-Coding RNAs in CD34+ Cells from Patients with Primary Myelofibrosis and Its Clinical Correlations. *Leuk Lymphoma*. 2015 Feb;56(2):492-6.
31. Norfo R, Zini R, Pennucci V, Bianchi E, Salati S, Guglielmelli P, Bogani C, Fanelli T, Mannarelli C, Rosti V, Pietra D, Salmoiraghi S, Bisognin A, Ruberti S, Rontauoli S, Sacchi G, Prudente Z, Barosi G, Cazzola M, Rambaldi A, Bortoluzzi S, Ferrari S, Tagliafico E, Vannucchi AM, and **Manfredini R**. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis. *BLOOD*, 2014, 124(13), pp. e21–e32

Modena, 25.06.26